Fleischman William, Ross Joseph S, Melnick Edward R, Newman David H, Venkatesh Arjun K
Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, CT.
Robert Wood Johnson Foundation Clinical Scholars Program, Yale School of Medicine, New Haven, CT; Center for Outcomes Research, Yale-New Haven Hospital, New Haven, CT.
Ann Emerg Med. 2016 Aug;68(2):153-158.e4. doi: 10.1016/j.annemergmed.2016.01.014. Epub 2016 Mar 10.
The Open Payments program requires reporting of payments by medical product companies to teaching hospitals and licensed physicians. We seek to describe nonresearch, nonroyalty payments made to emergency physicians in the United States.
We performed a descriptive analysis of the most recent Open Payments data released to the public by the Centers for Medicare & Medicaid Services covering the 2014 calendar year. We calculated the median payment, the total pay per physician, the types of payments, and the drugs and devices associated with payments to emergency physicians. For context, we also calculated total pay per physician and the percentage of active physicians receiving payments for all specialties.
There were 46,405 payments totaling $10,693,310 to 12,883 emergency physicians, representing 30% of active emergency physicians in 2013. The percentage of active physicians within a specialty who received a payment ranged from 14.6% in preventive medicine to 91% in orthopedic surgery. The median payment and median total pay to emergency physicians were $16 (interquartile range $12 to $68) and $44 (interquartile range $16 to $123), respectively. The majority of payments (83%) were less than $100. Food and beverage (86%) was the most frequent type of payment. The most common products associated with payments to emergency physicians were rivaroxaban, apixaban, ticagrelor, ceftaroline, canagliflozin, dabigatran, and alteplase.
Nearly a third of emergency physicians received nonresearch, nonroyalty payments from industry in 2014. Most payments were of small monetary value and for activities related to the marketing of antithrombotic drugs.
“公开支付”计划要求医疗产品公司报告向教学医院和执业医师的付款情况。我们试图描述美国医疗产品公司向急诊医师支付的非研究、非版税款项。
我们对医疗保险和医疗补助服务中心向公众发布的涵盖2014日历年的最新“公开支付”数据进行了描述性分析。我们计算了付款中位数、每位医师的总付款额、付款类型以及与向急诊医师付款相关的药品和器械。为作比较,我们还计算了所有专科每位医师的总付款额以及获得付款的在职医师百分比。
共有46405笔付款,总计10693310美元,支付给了12883名急诊医师,占2013年在职急诊医师的30%。各专科中获得付款的在职医师百分比从预防医学的14.6%到整形外科的91%不等。急诊医师的付款中位数和总付款中位数分别为16美元(四分位距为12美元至68美元)和44美元(四分位距为16美元至123美元)。大多数付款(83%)低于100美元。食品和饮料(86%)是最常见的付款类型。与向急诊医师付款相关的最常见产品是利伐沙班、阿哌沙班、替格瑞洛、头孢洛林、卡格列净、达比加群和阿替普酶。
2014年,近三分之一的急诊医师从行业获得了非研究、非版税款项。大多数付款金额较小,且与抗血栓药物的营销活动有关。